NASDAQ$SLN
Silence Therapeutics Plc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Silence Therapeutics reported full year financial results and provided a business update.
Silence Therapeutics reported its full year 2024 financial results. The company ended the year with over $147 million in cash, cash equivalents and short-term investments and is extending its projected cash runway into 2027 by prioritizing divesiran in PV and programs in rare conditions.
- Cash, cash equivalents, and short-term investments were $147.3 million at the end of December 2024.
- Collaboration revenue was $43.1 million for the year ended December 31, 2024.
- Research and development (R&D) expenses were $67.9 million for the year ended December 31, 2024.
- Net loss was $45.3 million for the year ended December 31, 2024.
Headline financials
Revenue & EPS history
Silence Therapeutics · Revenue · Quarterly
$24.9M
Forward guidance
Silence announced that it will only initiate the zerlasiran Phase 3 CVOT study once a partner is secured and is extending its projected cash runway into 2027. The Company plans to prioritize development of divesiran in PV and programs in rare conditions with high unmet needs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-2.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+4.4%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+11.3%
Q2 2023
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q1 2026 | -5.8% | -7.7% | -16.3% | |
| Q4 2025 | -6.0% | +4.2% | -0.7% | |
| Q3 2025 | +2.9% | +7.7% | +11.5% | |
| Q2 2025 | +0.2% | +5.1% | +7.0% | |
| Q1 2025 | -1.7% | +26.6% | +31.3% | |
| Q4 2024 | -1.0% | -6.1% | -27.9% | |
| Q3 2024 | -16.7% | -54.3% | -57.7% | |
| Q4 2023 | -8.0% | -7.3% | -14.4% | |
| Q3 2023 | +4.6% | +1.0% | +74.5% | |
| Q2 2023 | +11.3% | +14.2% | +62.6% | |
| Q1 2023 | -7.2% | +1.9% | +3.9% | |
| Q4 2022 | -6.9% | -6.6% | -35.8% | |
| Q3 2022 | +10.7% | +17.4% | +32.1% | |
| Q2 2022 | -2.3% | -3.6% | +22.1% | |
| Q1 2022 | -1.8% | -14.6% | -6.1% | |
| Q4 2021 | -0.8% | +6.7% | +0.6% | |
| Q2 2021 | -14.3% | -11.8% | -9.7% | |
| Q1 2021 | +0.2% | +13.2% | +9.6% | |
| Q4 2020 | +0.2% | +0.2% | +13.7% | |
| Q3 2020 | -2.5% | -9.0% | -13.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro